SepternaSEPN
Recorded

Septerna UBS Global Biopharma Conference 2026

Review the key takeaways and the transcript of this earnings call.

Period 2026Duration30 minParticipants3

Transcript

Preview the first fifteen paragraphs, organized by speaker.

Alice NettletonSMID Biotech Analyst

Good afternoon, everybody. Welcome to the next session at the UBS Global Biopharma Conference. I'm Alice Nettleton, one of the SMID biotech analysts at UBS. Happy to introduce the team from Septerna, Jeff Finer, CEO and Co-Founder, and Liz Bhatt, President and COO. Great to see you, Jeff and Liz. Thank you so much for joining us. To start off, I'll hand it over to Jeff to go through some slides for a presentation for maybe 15 minutes, and then we'll have a Q&A after that.

Jeffrey FinerCEO and Co-Founder

Okay. Thanks, Alice, and thanks to the UBS team for inviting us. For those of you who aren't familiar with Septerna, we're a company focused entirely on GPCRs, or G protein-coupled receptors. At the founding of the company, we figured out a new way to do drug discovery for GPCRs. I don't have time today to tell you much about the platform, but I will make some forward-looking statements, so take that into consideration. But that platform has quickly evolved into a very interesting portfolio of products, and we'll spend time on a couple of these today. SEP-479 is our oral small molecule drug for hypoparathyroidism. It's focused on the parathyroid hormone receptor called PTH1R. It's currently in an ongoing phase I trial.

Jeffrey FinerCEO and Co-Founder

We anticipate that that phase I trial will read out in the first quarter of 2027, so we're excited about that dataset, and we can spend some of the time today talking about what we hope to see in that dataset. Our second program, which is fairly newly announced, is SEP-204. It's going after a target called TSHR for Graves' disease and thyroid eye disease. We just presented, just about a week and a half ago, data at the American Thyroid Association Conference, preclinical data. This is a compound that's moving along quite nicely on the way to starting in the clinic. It should be in the clinic in Q1 of 2027 as well, so it'd be great to introduce you to that as well. A couple other programs that we may only touch on more briefly today.

Jeffrey FinerCEO and Co-Founder

One focus is on a mast cell target called MRGPRX2, where we have a compound, SEP-631, that completed a phase I trial in March, and we announced that data. We're excited about that compound. We think we've got a potential best-in-class profile for that compound. It is currently in between phase I and phase II, as we are developing a clinical strategy around which indications to go after next. The newest addition to our pipeline, the fourth program there, is a second PTH receptor small molecule agonists program. This is for osteoporosis, and one thing that distinguishes the osteoporosis program from the hypoparathyroidism program is that for osteoporosis, you need to have a short-acting compound. There is something about bone biology and the interaction with the PTH receptor.

Jeffrey FinerCEO and Co-Founder

We know from peptides that short-acting peptides are anabolic for bone, they cause bone formation, whereas for hypoparathyroidism, we actually want full-day calcium control, so we want a long-acting compound there. Beyond those, we actually have a few earlier-stage programs as well. We won't talk about those. We also have a quite substantial partnership with Novo that we put in place about a little over a year ago now, middle of 2025. That collaboration is working on five targets, four concurrent programs. It's going quite well. Just last week, we announced in our quarterly earnings that Novo had selected the first development candidate from the collaboration and plans to move that forward. What I'd like to do with time today is really spend it on two programs, the hypoparathyroidism program and the Graves' program.

Jeffrey FinerCEO and Co-Founder

SEP-479 came out of our platform, which we call the Native Complex Platform, and we developed an oral small molecule that's actually quite potent. What we're looking at here is the PTH receptor in magenta, and you can see in green the PTH peptide. PTH peptide basically binds in the transmembrane domain and goes all the way up on the extracellular domain. This is a receptor that many companies have tried to find small molecules for literally decades, and struck out. We found not one binding pocket, but two distinct binding pockets for oral small molecules that allow those compounds to completely mimic what the peptides do. In every preclinical model system that we've looked at, the small molecule PTH small molecules for the PTH receptor, including SEP-479, do exactly what the PTH peptides do. We optimized that with our platform and led to this candidate.

Jeffrey FinerCEO and Co-Founder

As I said, 479 is a potent oral small molecule. As I'll show you, it has some great activity in preclinical models. Just for the sake of time, we'll only focus on one of them today, one of the preclinical models. It showed great activity in a rat surgical model of hypoparathyroidism. What I'll share today is some monkey PK/PD data. That is in a healthy monkey, and it's a good predictor of what we hope to see in our healthy patient trial that's ongoing. It's got great pharmaceutical properties. We projected that it would have a half-life between 40 and 80 hours, and we ended up at the long end of that.

Jeffrey FinerCEO and Co-Founder

We've got a compound that now has a half-life of three to four days, which we think is actually quite important because it will allow us to actually achieve ideally very stable calcium control throughout the day. Well tolerated in GLP tox studies, and as I said, it's in phase I trial right now. With regard to that monkey data, this is a seven-day study in healthy monkeys. The thing that's important to realize is that healthy monkeys, as well as healthy humans in our clinical trial, generally have intact parathyroid glands, which is quite different than hypoparathyroidism patients, who have frequently lost their parathyroid glands. In a healthy animal, and a healthy human, the result of having those glands is that there's an endocrine feedback loop that tries to keep calcium stable.

Jeffrey FinerCEO and Co-Founder

With that endocrine feedback loop, what we expect to see when we dose our drug is endogenous PTH levels going down, and this is exactly what you're seeing here in the left graph. This is endogenous PTH levels, and you can see its percentage change. We're lowering that by about 80% or so. Here, once that is down and hits that threshold, you can see it kind of bottoms out there. We've got four different doses. As we dose up higher, we get increasing levels of calcium beyond that. The question is, what's the relevant amount of calcium increase that we hope to see? Well, the advantage that we have is that there have been peptides developed before us. Yorvipath from Ascendis, which is currently approved in drug for injectable peptide for hypoparathyroidism.

Jeffrey FinerCEO and Co-Founder

If we look at their starting dose and then retrospectively look at what it did in its phase I healthy volunteer studies, it increased calcium about 0.5 mg per deciliter, which was appropriate for a starting dose, and then up to about one mg per deciliter at higher doses. Moving on to our phase I trial. This is a very standard single ascending dose, multiple ascending dose design. Multiple cohorts. It's being run in Australia. We estimate about 150 subjects in this study. We're also planning to do a food effect study as well. We're not expecting a food effect, but we want to work that out in the clinic, make sure that's the case. What we have disclosed a couple of months back is that SEP-479 has a half-life of about three to four days.

Jeffrey FinerCEO and Co-Founder

Again, this is something that will allow us to hopefully have very tight control with a once-daily dosing regimen. The multiple ascending dose portion of the trial was then extended to about 14 days, and the purpose of that was to try to achieve basically steady state levels. A good rule of thumb is that about four to five half-lives will get you to steady state, and we think at about 14 days, we should be getting close to that. As I mentioned, in terms of what we hope to see, we're hoping to see endogenous PTH levels go down about 50% and serum calcium to go up about 0.5 mg per deciliter to inform what would be a starting dose in hypoparathyroidism patients. As many of you know, hypoparathyroidism is a disease where the PTH replacement needs to be titrated on a patient-by-patient basis.

Jeffrey FinerCEO and Co-Founder

We want to be at that sort of starting dose and then be able to titrate a bit higher. We are looking for levels up around one mg per deciliter at our high doses. As I said, this trial should wrap up in the first quarter. Just in the last few minutes, I want to introduce you to SEP-204, which is our new oral small molecule for Graves' disease and thyroid eye disease, which we announced just for the first time a couple of weeks ago. We're looking at different structure here. This is the TSH receptor. You can see that it undergoes a very large conformational change from an inactive state in blue to an active state in that more magenta color. You can see a big conformational change on the extracellular domain.

Jeffrey FinerCEO and Co-Founder

Inside the receptor, you can see a bit of a change there as well. Our goal was to come up with a compound that would prevent the binding of all autoantibodies. Graves' disease and thyroid eye disease are diseases of autoantibodies that are directed to this TSH receptor and lead to all the hallmarks of Graves' disease, including hyperthyroidism as well as thyroid eye disease. SEP-204 basically binds in that region. Here are some of the characteristics of the development candidate. It is a potent oral small molecule. One of the things that is actually quite important is that we have a selective compound. There are two very closely related receptors, FSH receptor and LH receptor. These are reproductive hormone receptors, and as Graves' disease is commonly found in women of reproductive years, we do not want to affect those reproductive hormone receptors.

Jeffrey FinerCEO and Co-Founder

Compound has excellent pharmaceutical properties, and we project this one also to be a once-daily oral dose as well. It has completed GLP toxicology studies, and all we saw there was signs of exaggerated on-target pharmacology, including hypothyroidism. Phase I is on track here to begin in Q1 of 2027. I am going to share just a little bit of the data that we shared again at the American Thyroid Association meeting just about a week and a half ago. SEP-204 is, in this case, dosed to a rat, but it is dosed after dosing a Graves' patient-derived antibody, which is called M22. That is shown in the diagram there. When M22 is dosed, you see in the upper graph, thyroid T4 hormone levels starting to go up, and then about 18 hours later, we start dosing SEP-204.

Jeffrey FinerCEO and Co-Founder

For the animals that do not receive SEP-204, this is in the black curve at the top, you can see the thyroid hormone levels go up and then plateau. But we see two doses, one and three milligrams per kilogram, where you can see the thyroid T4 hormone levels basically normalizing. That little thin gray band that you see there is the normal hormone level. Both of those land us in that normal range, which is exciting. We can also go up to a higher dose of 10 mgs per kilogram, and there we get a more comprehensive suppression of the receptor, and that decreases thyroid hormone levels. The reason this is exciting to us is that it provides a suggestion that we may have dose optionality.

FULL TRANSCRIPT

Continue the full translated transcript in StockNow.

Access every statement, the English original, and speaker-by-speaker history with StockNow Pro.

View the full transcript with Pro

Other earnings calls that day

View calls from this day